Differential effects of bilateral dopamine depletion in neonatal and adult rats

Neuroscience and Biobehavioral Reviews

Volumn 21, Issue 4, 1997, Pages 425-435

  Moy, Sheryl S ^a   Criswell, H E ^a   Breese, G R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine; Dopamine; Lesch Nyhan syndrome; Motor behavior; Neonatal rat; Parkinson's disease; Self injurious behavior

Indexed keywords

DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOMUTILATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; LESCH NYHAN SYNDROME; LOCOMOTION; MOTOR PERFORMANCE; NEUROTRANSMISSION; NEWBORN; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

ADULT; AGING; ANIMALS; ANIMALS, NEWBORN; BRAIN; BRAIN CHEMISTRY; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; RATS;

EID: 0030906741     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0149-7634(96)00040-1     Document Type: Article

References (124)

1. 1. Albin, R. L.; Young, A. B.; Penny, J. B., The functional neuroanatomy of basal ganglia disorders. Trends in Neurological Science, 12, 366-375 1989.
2. 2. Baumeister, A. A.; Frye, G. D., The biochemical basis of the behavioral disorder in the Lesch-Nyhan syndrome. Neuroscience and Biobehavioral Reviews, 9, 169-178 1985.
3. 3. Baumeister, A. A.; Frye, G. D., Involvement of the midbrain reticular formation in self-injurious behavior, stereotyped behavior, and analgesia induced by intranigral microinjection of muscimol. Brain Research, 369, 231-242 1986.
4. 4. Berger, T. W; Kaul, S.; Stricker, E. M.; Zigmond, M. J., Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Research, 336, 354-358 1985.
5. 5. Breese, G. R.; Baumeister, A. A.; McCown, T. L; Emerick, S. G.; Frye, G. D.; Crotty, K.; Mueller, R. A., Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. Journal of Pharmacology and Experimental Therapeutics, 231 (2), 343-354 1984.
6. 6. Breese, G. R.; Baumeister, A. A.; McCown, T. J.; Emerick, S. G.; Frye, G. D.; Mueller, R. A., Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome. Pharmacology Biochemistry and Behavior, 21, 459-461 1984.
7. 7. Breese, G. R.; Baumeister, A. A.; Napier, T. C.; Frye, G. D.; Mueller, R. A., Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. Journal of Pharmacology and Experimental Therapeutics, 235 (2), 287-295 1985.
8. 8. Breese, G. R.; Cooper, B. R. Relationship of dopamine neural systems to the maintenance of self-stimulation. In: Domino, E. F.; Davis, J. M., eds. Neurotransmitter balances regulating behavior. Ann Arbor: E. F. Domino and J. M. Davis; 1975:37-56.
9. 9. Breese, G. R.; Criswell, H. E.; Duncan, G. E.; Mueller, R. A., A dopamine deficiency model of Lesch-Nyhan disease - the neonatal-6-OHDA-lesioned rat. Brain Research Bulletin, 25, 477-484 1990.
10. 10. Breese, G. R.; Duncan, G. E.; Napier, T. C.; Bondy, S. C.; Iorio, L. C.; Mueller, R. A., 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1-and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. Journal of Pharmacology and Experimental Therapeutics, 240 (1), 167-176 1987.
11. 11. Breese, G. R.; Howard, J. L.; Leahy, J. P., Effect of 6-hydroxydoapmine on electrical self stimulation of the brain. British Journal of Pharmacology, 43 (1), 255-257 1971.
12. 12. Breese, G. R.; Hulebak, K. L.; Napier, T. C.; Baumeister, A.; Frye, G.; Mueller, R. A., Enhanced muscimol-induced behavioral responses after 6-OHDA lesions: Relevance to susceptibility for self-mutilation behavior in neonatally lesioned rats. Psychopharmacology, 91, 356-362 1987.
13. 13. Breese, G. R.; Mueller, R. A., SCH-23390 antagonism of a D2 dopamine agonist depends upon catecholaminergic neurons. European Journal of Pharmacology, 113, 109-114 1985.
14. 14. Breese, G. R.; Mueller, R. A.; Napier, T. C.; Duncan, G. E., Neurobiology of D1 dopamine receptors after neonatal-6-OHDA treatment: relevance to Lesch-Nyhan disease. Advances in Experimental Medicine and Biology, 204, 197-215 1986.
15. 15. Breese, G. R.; Napier, T. C.; Mueller, R. A., Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D-1 dopamine receptors in neonatally lesioned rats. Journal of Pharmacology and Experimental Therapeutics, 234 (2), 447-455 1985.
16. 16. Breese, G. R.; Smith, R. D.; Cooper, B. R.; Grant, L. D., Alterations in consummatory behavior following intracisternal injection of 6-hydroxydopamine. Pharmacology Biochemistry and Behavior, 1, 319-328 1973.
17. 17. Breese, G. R.; Traylor, T. D., Effect of 6-hydroxydopamine on brain norepinephrine and dopamine: Evidence for selective degeneration of catecholamine neurons. Journal of Pharmacology and Experimental Therapy, 174 (3), 413-420 1970.
18. 18. Breese, G. R.; Traylor, T. D., Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: Effects of 6-hydroxydopamine. British Journal of Pharmacology, 44 (2), 210-222 1972.
19. 19. Broaddus, W. C.; Bennett, J. P. Jr, Postnatal development of striatal dopamine function. II. Effects of neonatal 6-hydroxydopamine treatments on D1 and D2 receptors, adenylate cyclase activity and presynaptic dopamine function. Developmental Brain Research, 52, 273-277 1990.
20. 20. Bruno, J. P.; Jackson, D.; Zigmond, M. J.; Stricker, E. M., Effect of dopamine-depleting brain lesions in rat pups: Role of striatal serotonergic neurons in behavior. Behavioral Neuroscience, 101 (6), 806-811 1987.
21. 21. Bruno, J. P.; Snyder, A. M.; Stricker, E. M., Effect of dopamine-depleting brain lesions on suckling and weaning in rats. Behavioral Neuroscience, 98 (1), 156-161 1984.
22. 22. Bruno, J. P.; Stricker, E. M.; Zigmond, M. J., Rats given dopamine-depleting brain lesions as neonates are subsensitive to dopaminergic antagonists as adults. Behavioral Neuroscience, 99 (4), 771-775 1985.
23. 23. Bruno, J. P.; Zigmond, M. J.; Stricker, E. M., Rats given dopamine-depleting brain lesions as neonates do not respond to acute homeo-static imbalances as adults. Behavioral Neuroscience, 100 (1), 125-128 1986.
24. 24. Brus, R.; Plech, A.; Kostrzewa, R. M., Enhanced quinpirole response in rats lesioned neonatally with 5,7-dihydroxytryptamine. Pharmacology Biochemistry and Behavior, 50 (4), 649-653 1995.
25. 25. Carlsson, M.; Carlsson, A., The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. Journal of Neural Transmission, 75, 221-226 1989.
26. 26. Castaneda, E.; Whishaw, I. Q.; Lermer, L.; Robinson, T. E., Dopamine depletion in neonatal rats: Effects on behavior and striatal dopamine release assessed by intracerebral microdialysis during adulthood. Brain Research, 508, 30-39 1990.
27. 27. Chen, J. F.; Weiss, B., Ontogenetic expression of D2 dopamine receptor MRNA in rat corpus striatum. Developmental Brain Research, 63, 95-104 1991.
28. 28. Christie, R.; Bay, C.; Kaufman, I. A.; Bakay, B.; Borden, M.; Nyhan, W. L., Lesch-Nyhan disease: Clinical experience with nineteen patients. Developmental Medicine and Child Neurology, 24, 293-306 1982.
29. 29. Cooper, A. J.; Wooller, S.; Mitchell, I. J., Elevated striatal Fos immunoreactivity following 6-hydroxydopamine lesioning of the rat is mediated by excitatory amino acid transmission. Neuroscience Letters, 194, 73-76 1995.
30. 30. Cooper, B. R.; Breese, G. R.; Grant, L. D.; Howard, J. L., Effects of 6-hydroxydopamine treatments on active avoidance responding: Evidence for involvement of brain dopamine. Journal of Pharmacology and Experimental Therapeutics, 185 (2), 358-370 1973.
31. 31. Cooper, B. R.; Cott, J. M.; Breese, G. R., Effects of catecholamine-depleting drugs and amphetamine on self-stimulation of brain following various 6-hydroxydopamine treatments. Psychopharmacologia (Berlin), 37, 235-248 1974.
32. 32. Cooper, B. R.; Howard, J. L.; Grant, L. D.; Smith, R. D.; Breese, G. R., Alteration of avoidance and ingestive behavior after destruction of central catecholamine pathways with 6-hydroxydopamine. Pharmacology Biochemistry and Behavior, 2, 639-649 1974.
33. 33. Criswell, H. E.; Johnson, K. B.; Mueller, R. A.; Breese, G. R., Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-Methyl-D-Aspartic Acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. Journal of Pharmacology and Experimental Therapeutics, 265 (2), 1001-1010 1993.
34. 34. Criswell, H. E.; Mueller, R. A.; Breese, G. R., Priming of D1-dopamine receptor responses: Long-lasting behavioral supersensitivity to a D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. Journal of Neuroscience, 9 (1), 125-133 1989.
35. 35. Criswell, H. E.; Mueller, R. A.; Breese, G. R., Long-term D1-dopamine receptor sensitization in neonatal 6-OHDA-lesioned rats is blocked by an NMDA antagonist. Brain Research, 512, 284-290 1990.
36. 36. Curran, T.; Morgan, J. I., Memories of fos. Bio Essays, 7, 255-258 1988.
37. 37. de Brabander, J. M.; de Bruin, J. P. C.; van Eden, C. G., Comparison of the effects of neonatal and adult medial prefrontal cortex lesions on food hoarding and spatial delayed alteration. Behavioral Brain Research, 42, 67-75 1991.
38. 38. Descarries, L.; Soghomonian, J. J.; Garcia, S.; Doucet, G.; Bruno, J. P., Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine. Brain Research, 569, 1-13 1992.
39. 39. Dewar, K. M.; Soghomonian, J. J.; Bruno, J. P.; Descarries, L.; Reader, T. A., Elevation of dopamine D2 but not D1 receptors in adult rat neostriatum after neonatal 6-hydroxydopamine denervation. Brain Research, 536, 287-296 1990.
40. 40. Duncan, G. E.; Breese, G. R.; Criswell, H. E.; Johnson, K. B.; Schambra, U. B.; Mueller, R. A.; Caron, M. G.; Fremeau, R. T. Jr, D1 dopamine receptor binding and mRNA levels are not altered after neonatal 6-hydroxydopamine treatment: Evidence against dopamine-mediated induction of D1 dopamine receptors during postnatal development. Journal of Neurochemistry, 61 (4), 1255-1262 1993.
41. 41. Duncan, G. E.; Criswell, H. E.; McCown, T. L.; Paul, I. A.; Mueller, R. A.; Breese, G. R., Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. Journal of Pharmacology and Experimental Therapeutics, 243 (3), 1027-1034 1987.
42. 42. Ferrer, I.; Costell, M.; Grisolia, S., Lesch-Nyhan syndrome-like behavior in rats from caffeine ingestion: Changes in HGPRTase activity, urea and some nitrogen metabolism enzymes. FEBS Letters, 141 (2), 275-278 1982.
43. 43. Fremeau, R. T. Jr.; Duncan, G. E.; Fornaretto, M.-G.; Dearry, A.; Gingrich, J. A.; Breese, G. R.; Caron, M. G., Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proceedings of the National Academy of Sciences USA, 88, 3772-3776 1991.
44. 44. Gancher, S.; Mayer, A., Sensitization to apomorphine-induced rotational behavior in 6-OHDA lesioned rats: effects of NMDA antagonists on drug responses. Brain Research, 682, 63-68 1995.
45. 45. Gerfen, C. R., The neostriatal mosaic: multiple levels of compartmental organization. Journal of Neural Transmission, 36 (Suppl), 43-59 1992.
46. 46. Gerfen, C. R.; Herkenham, M.; Thibault, J., The neostriatal mosaic: II. Patch-and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. Journal of Neuroscience, 7 (12), 3915-3934 1987.
47. 47. Goldstein, M.; Kuga, S.; Kusano, N.; Meller, E.; Dancis, J.; Schwarcz, R., Dopamine agonist induced self-mutilative biting behavior in monkeys with unilateral ventromedial tegmental lesions of the brainstem: Possible pharmacological model for Lesch-Nyhan syndrome. Brain Research, 367, 114-120 1986.
48. 48. Goldstein, M.; Kuga, S.; Shimizu, Y.; Meller, E., The pathophysiological functions mediated by D1 dopamine receptors. Advances in Experimental Medicine and Biology, 204, 189-195 1986.
49. 49. Gong, L.; Kostrzewa, R.; Brus, R.; Fuller, R. W.; Perry, K. W., Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats. Developmental Brain Research, 76, 59-65 1993.
50. 50. Gong, L.; Kostrzewa, R. M.; Fuller, R. W.; Perry, K. W., Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. Journal of Pharmacology and Experimental Therapeutics, 261 (3), 1000-1007 1992.
51. 51. Graybiel, A. M., Neurotransmitters and neuromodulators in the basal ganglia. Trends in Neurological Science, 13, 244-254 1990.
52. 52. Graybiel, A. M.; Aosaki, T.; Flaherty, A. W., The basal ganglia and adaptive motor control. Science, 265, 1826-1831 1994.
53. 53. Greenamyre, J. T.; Eller, R. V.; Zhang, Z.; Ovadia, A.; Kurian, R.; Gash, D. M., Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Annals of Neurology, 35, 655-661 1994.
54. 54. Hartgraves, S. L.; Randall, P. K., Dopamine agonist-induced stereotypic grooming and self-mutilation following striatal dopamine depletion. Psychopharmacology, 90, 358-363 1986.
55. 55. Hornykiewicz, O., Parkinson's disease: From brain homogenate to treatment. Federation Proceedings, 32, 183-190 1973.
56. 56. Howard, J. L.; Grant, L. D.; Breese, G. R., Effects of intracisternal 6-hydroxydopamine treatment on acquisition and performance of rats in a double T-maze. Journal of Comparative Physiology and Psychology, 86 (6), 995-1007 1974.
57. 57. Huang, K.-X.; Walters, J. R., 1 receptor stimulation inhibits dopamine cell activity after reserpine treatment but not after chronic SCH 23390: An effect blocked by N-methyl-D-aspartate antagonists. Journal of Pharmacology and Experimental Therapeutics, 260 (1), 409-416 1992.
58. 58. Jankovic, J.; Caskey, T. C.; Stout, J. T.; Butler, I. J., Lesch-Nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters. Annals of Neurology, 23, 466-469 1988.
59. 59. Johnson, B. J.; Bruno, J. P., D1 and D2 receptor mediation of sensorimotor behavior in rats depleted of dopamine during development. Behavioral Brain Research, 47, 49-58 1992.
60. 60. Johnson, B. J.; Bruno, J. P., D1 and D2 receptor contributions to ingestive and locomotor behavior are altered after dopamine depletions in neonatal rats. Neuroscience Letters, 118, 120-123 1990.
61. 61. Johnson, K. R.; Criswell, H. E.; Jensen, K. F.; Simson, P. E.; Mueller, R. A.; Breese, G. R., Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: Behavioral effects and induction of c-fos-like immunoreactivity. Journal of Pharmacology and Experimental Therapeutics, 262 (2), 855-865 1992.
62. 62. Karler, R.; Calder, L. D.; Chaudhry, I. A.; Turkanis, S. A., Blockade of 'reverse tolerance' to cocaine and amphetamine by MK-801. Life Science, 45, 599-606 1989.
63. 63. Klockgether, T.; Turski, L., Toward an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia. Annals of Neurology, 34, 585-593 1993.
64. 64. Klockgether, T.; Turski, L., NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats. Annals of Neurology, 28, 539-546 1990.
65. 65. Klockgether, T.; Turski, L.; Honore, T.; Zhang, Z.; Gash, D. M.; Kurlan, R.; Greenamyre, J. T., The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Annals of Neurology, 30, 717-723 1991.
66. 66. Kopin, I. J., Neurotransmitters and the Lesch-Nyhan syndrome. New England Journal of Medicine, 305, 1148-1149 1981.
67. 67. Kostrzewa, R. M., Dopamine receptor supersensitivity. Neuroscience and Biobehavioral Reviews, 19, 1-17 1995.
68. 68. Kostrzewa, R. M.; Gong, L., Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacology Biochemistry and Behavior, 39, 677-682 1991.
69. 69. Kostrzewa, R. M.; Hamdi, A., Potentiation of spiperone-induced oral activity in rats after neonatal 6-hydroxydopamine. Pharmacology Biochemistry and Behavior, 38, 215-218 1991.
70. 70. Lesch, M.; Nyhan, W. L., A familial disorder of uric acid metabolism and central nervous system function. American Journal of Medicine, 36, 561-570 1964.
71. 71. Lloyd, K. G.; Hornykiewicz, O.; Davidson, L.; Shannak, K.; Farley, I.; Goldstein, M.; Shibuta, M.; Kelley, W. N.; Fox, I. H., Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. New England Journal of Medicine, 305, 1106-1111 1981.
72. 72. Luthman, J.; Bolioli, B.; Tsutsumi, T.; Verhofstad, A.; Jonsson, G., Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Research Bulletin, 19, 269-274 1987.
73. 73. Luthman, J.; Lindqvist, E.; Ogren, S. O., Hyperactivity in neonatally dopamine-lesioned rats requires residual activity in mesolimbic dopamine neurons. Pharmacology Biochemistry and Behavior, 51 (1), 159-163 1995.
74. 74. Luthman, J.; Lindqvist, E.; Young, D.; Cowburn, R., Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine-and adenosine 3′:5′-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity. Experimental Brain Research, 83, 85-95 1990.
75. 75. Morelli, M.; Di Chiara, G., Agonist-induced homologous and heterologous sensitization to D-1 and D2-dependent contraversive turning. European Journal of Pharmacology, 141, 101-107 1987.
76. 76. Morelli, M.; Di Chiara, G., MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. European Journal of Pharmacology, 182, 611-612 1990.
77. 77. Morelli, M.; Fenu, S.; Pinna, A.; Di Chiara, G., Opposite effects of NMDA receptor blockade on dopaminergic D1-and D2-mediated behavior in the 6-hydroxydopamine model of turning: Relationship with c-fos expression. Journal of Pharmacology and Experimental Therapeutics, 260 (1), 402-408 1992.
78. 78. Morelli, M.; Pinna, A.; Fenu, S.; Carta, A.; Cozzolino, A.; Di Chiara, G., Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats. Synapse, 18, 288-293 1994.
79. 79. Morris, R. G. M.; Anderson, E.; Lynch, G.; Baudry, M., Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP-5. Nature (London), 319, 774-776 1986.
80. 80. Moy, S. S., Impaired acquisition and operant responding after neonatal dopamine depletion in rats. Pharmacology Biochemistry and Behavior, 52 (2), 433-441 1995.
81. 81. Moy, S. S.; Breese, G. R.; Eckerman, D. A., Altered activity patterns following neonatal 6-hydroxydopamine lesions to dopaminergic neurons: Effect of SKF-38393. Brain Research, 645, 49-60 1994.
82. 82. Mueller, K.; Saboda, S.; Palmour, R.; Nyhan, W. L., Self-injurious behavior produced in rats by daily caffeine and continuous amphetamine. Pharmacology Biochemistry and Behavior, 17, 613-617 1982.
83. 83. Neal-Beliveau, B. S.; Joyce, J. N., D1 and D2 dopamine receptors do not up-regulate in response to neonatal intrastriatal 6-hydroxydopamine lesions. Neuroscience Letters, 160, 77-80 1993.
84. 84. Obeso, J. A.; Luquin, M. R.; Artieda, J. Motor manifestations of basal ganglia diseases. Pharmacological studies in humans. In: Sandler, M., Feuerstein, G, Scatton, B. eds. Neurotransmitter interactions in the basal ganglia. New York: Raven Press; 1987:205-218.
85. 85. Ohno, M.; Yoshida, H.; Watanabe, S., NMDA receptor-mediated expression of Fos protein in the rat striatum following methamphetamine administration: Relation to behavioral sensitization. Brain Research, 665, 135-140 1994.
86. 86. Parent, A., Extrinsic connections of the basal ganglia. Trends in Neurological Science, 13 (7), 254-258 1990.
87. 87. Paul, M. L.; Graybiel, A. M.; David, J.-C.; Robertson, H. A., D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkonson's disease. Journal of Neuroscience, 12 (10), 3729-3742 1992.
88. 88. Potter, B. M.; Bruno, J. P., Food intake of rats depleted of dopamine as neonates is impaired by inhibition of catecholamine biosynthesis. Neuroscience Letters, 107, 295-300 1989.
89. 2 receptors, in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: A quantitative autoradiographic study. Brain Research, 606, 273-285 1993.
90. 90. Reid, M. S.; O'Conner, W. T.; Herrera-Marschitz, M.; Ungerstedt, U., The effects of intranigral GABA and dynorphin A injections on striatal dopamine and GABA release: Evidence that dopamine provides inhibitory regulation of striatal GABA neurons via D2 receptors. Brain Research, 519, 255-260 1990.
91. 91. Reiner, A.; Anderson, K. D., The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neruons: Conclusions based on recent findings. Brain Research Review, 15, 251-265 1990.
92. 92. Robertson, G. S.; Herrera, D. G.; Dragunow, M.; Robertson, H. A., L-dopa activates c-fos, expression in the striatum of 6-hydroxydopamine-lesioned rats. European Journal of Pharmacology, 159, 99-100 1989.
93. 93. Robertson, G. S.; Vincent, S. R.; Fibiger, H. C., Striatonigral projection neurons contain D1 dopamine receptor-activated c-fos. Brain Research, 523, 288-290 1990.
94. 94. Robertson, G. S.; Vincent, S. R.; Fibiger, H. C., D1 and D2 dopamine receptors differentially regulate c-fos expression in striatonigral and striatopallidal neurons. Neuroscience, 49, 285-296 1992.
95. 95. Robertson, H. A.; Peterson, M. R.; Murphy, K.; Robertson, G. S., D1-dopamine receptor agonists selectively activate striatal c-fos independent of rotational behaviour. Brain Research, 503, 346-349 1989.
96. 96. Rogers, D. C.; Dunnett, S. B., Hypersensitivity to α-methyl-ρ-tyrosine suggests that behavioural recovery of rats receiving neonatal 6-OHDA lesions is mediated by residual catecholamine neurones. Neuroscience Letters, 102, 108-113 1989.
97. 97. Sagar, S. M.; Sharp, F. R.; Curran, T., Expression of c-fos protein in brain: Metabolic mapping at the cellular level. Science, 240, 1328-1331 1988.
98. 98. Shaywitz, B. A.; Teicher, M. H.; Cohen, D. J.; Anderson, G. M.; Young, J. G.; Levitt, P., Dopaminergic but not noradrenergic mediation of hyperactivity and performance deficits in the developing rat pup. Psychopharmacology, 82, 73-77 1984.
99. 99. Silverstein, F. S.; Johnston, M. V.; Hutchinson, R. J.; Edwards, N. L., Lesch-Nyhan syndrome: CSF neurotransmitter abnormalities. Neurology, 35, 907-911 1985.
100. 100. Simson, P. E.; Johnson, K. B.; Jurevics, H. A.; Criswell, H. E.; Napier, T. C.; Duncan, G. E.; Mueller, R. A.; Breese, G. R., Augmented sensitivity of D1-dopamine receptors in lateral but not medial striatum after 6-hydroxydopamine-induced lesions in the neonatal rat. Journal of Pharmacology and Experimental Therapeutics, 263 (3), 1454-1463 1992.
101. 101. Sivam, S. P., D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: implications for self-injurious behavior. Brain Research, 500, 119-130 1989.
102. 102. Sivam, S. P.; Breese, G. R.; Krause, J. E.; Napier, T. C.; Mueller, R. A.; Hong, J. S., Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression. Journal of Neurochemistry, 49 (5), 1623-1633 1987.
103. 103. Sivam, S. P.; Krause, J. E., The adaptation of enkephalin, tachykinin and monoamine neurons of the basal ganglia following neonatal dopaminergic denervation is dependent on the extent of dopamine depletion. Brain Research, 536, 169-175 1990.
104. 104. Sivam, S. P.; Krause, J. E.; Breese, G. R.; Hong, J. S., Dopamine-dependent postnatal development of enkephalin and tachykinin neurons of rat basal ganglia. Journal of Neurochemistry, 56 (5), 1499-1508 1991.
105. 105. Smith, R. D.; Cooper, B. R.; Breese, G. R., Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: Evidence for involvement of brain dopamine. Journal of Pharmacology and Experimental Therapeutics, 185 (3), 609-6191 1973.
106. 106. Snyder, A. M.; Stricker, E. M.; Zigmond, M. J., Stress-induced neurological impairments in an animal model of parkinsonism. Annals of Neurology, 18 (5), 544-551 1985.
107. 107. Sokoloff, P.; Giros, B.; Martres, M. P.; Bouthenet, M. L.; Schwartz, J. C., Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146-151 1990.
108. 108. Sourkes, T. L. Disorders of the basal ganglia. In: Siegal, G. J., ed. Basic neurochemistry: Molecular, cellular, and medical aspects. New York: Raven Press; 1989:811-825.
109. 109. Stachowiak, M. K.; Bruno, J. P.; Snyder, A. M.; Stricker, E. M.; Zigmond, M. J., Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Research, 291, 164-167 1984.
110. 110. Stellar, J. R.; Waraczyriski, M.; Bruno, J. P., Neonatal dopamine depletions spare lateral hypothalamic stimulation reward in adult rats. Pharmacology Biochemistry and Behavior, 30, 365-370 1988.
111. 111. Stout, J. T., Caskey, C. T. Hypoxanthine phosphoribosyltransferase deficiency: The Lesch-Nyhan syndrome and gouty arthritis. In: Scriver, C. R, Beaudet, A. L., Sly, W. S., Valle, D., eds. The metabolic basis of inherited disease, vol. 1. New York: McGraw-Hill, Inc.; 1989:1007-1028.
112. 112. Strange, P. G., New insights into dopamine receptors in the central nervous system. Neurochemistry International, 22 (3), 223-236 1993.
113. 113. Sunahara, R. K.; Guan, H. C.; O'Dowd, B. F.; Seeman, P.; Laurier, L. G.; Ng, G.; George, S. R.; Torchia, J.; Van Tol, H. H. M.; Niznik, H. B., Cloning of a gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature, 350, 614-619 1991.
114. 114. Swan, J. H.; Meldrum, B. S., Protection by NMDA antagonists against selective cell loss following transient ischaemia. Journal of Cerebral Blood Flow and Metabolism, 10, 343-351 1990.
115. 115. Torres, G.; Rivier, C., Cocaine-induced expression of striatal c-fos in the rat is inhibited by NMDA receptor antagonists. Brain Research Bulletin, 30, 173-176 1993.
116. 116. Towle, A. C.; Criswell, H. E.; Maynard, E. H.; Lauder, J. M.; Joh, T. H.; Mueller, R. A.; Breese, G. R., Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: An anatomical, biochemical and pharmacological study. Pharmacology Biochemistry and Behavior, 34, 367-374 1989.
117. 117. Ujike, H.; Tsuchida, H.; Kanzaki, A.; Akiyama, K.; Otsuki, S., Competitive and noncompetitive N-methyl-D-aspartate antagonists fail to prevent the induction of methamphetamine-induced sensitization. Life Science, 50, 1673-1681 1992.
118. 118. Van Tol, H. H. M.; Brunzow, J. R.; Guan, H. C.; Sunahara, R. K.; Seeman, P.; Niznik, H. B.; Civelli, O., Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614 1991.
119. 119. Walters, J. R.; Bergstrom, D. A.; Carlson, J. H.; Chase, T. N.; Braun, A. R., D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science, 236, 719-722 1987.
120. 120. Watts, R. W. E.; Spellacy, E.; Gibbs, D. A.; Allsop, J.; McKeran, R. O.; Slavin, G. E., Clinical, postmortem, biochemical and therapeutic observations on the Lesch-Nyhan syndrome with particular reference to the neurological manifestations. Quarterly Journal of Medicine, 51 (201), 43-78 1982.
121. 121. Weihmuller, F. B.; Bruno, J. P., Age-dependent plasticity in the dopaminergic control of sensorimotor development. Behavioral Brain Research, 35, 95-109 1989.
122. 122. Wolf, M. E.; Jeziorski, M., Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization. Brain Research, 613, 291-294 1993.
123. 123. Wong, D. F.; Harris, J. C.; Singer, H.; Sakkubai, N.; Yokoi, F.; Marenco, S.; Dannals, R. F.; Ravert, H. T.; Gjedde, A.; Evans, A.; Rousset, O.; Bryan, R. N.; Yaster, M.; Kuhar, M. J.; Breese, G. R., In vivo dopamine transporters are markedly reduced in Lesch Nyhan disease compared to Rett and Tourette syndromes and normal subjects. Proceedings of the National Academy of Science, 93, 5539-5543 1996.
124. 124. Zigmond, M. J.; Stricker, E. M., Parkinson's disease: Studies with an animal model. Life Science, 35 (1), 5-18 1984.